investors hero background type

Nanobiotix is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment.

NBTXR3 – Nanobiotix’s novel, first-in-class lead product candidate aims to expand the benefits of radiotherapy for millions of cancer patients. NBTXR3 is being evaluated both as a single agent activated by radiotherapy alone, and as a combination product with other anti-cancer therapies including chemotherapy and immune checkpoint inhibitors.

Featured Videos

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.